Come join us at the World PreClinical Congress in Boston, June 12-16. Daniel will be presenting data on how our SynFire technology can accelerate CNS Drug Discovery and Neurotox Assessments.
Addressing Relevant Physiological Readouts for CNS Drug Discovery
Daniel Haag, Ph.D., CSO, NeuCyte
High attrition rates of novel CNS drugs indicate that current preclinical testing fail to meet the unmet needs of patients. NeuCyte supports the early phases of CNS drug discovery programs for Lead Compound Optimization. Based on our SynFireTM technology, NeuCyte's human neural in vitro platforms are uniquely suited for assessing relevant higher order electrophysiology readouts allowing for a more reliable predictor of drug efficacy and potential CNS Safety/Toxicology.